Why is Oxford BioMedica stock sliding today?

Oxford BioMedica shares experienced a 1.3% drop, trading at 486.5 pence on Tuesday. The decline follows investors' reaction to a more cautious analyst outlook concerning the cell-and-gene therapy company after its recent revenue guidance reduction. This move leaves the stock below its 52-week high of 950 pence and highlights a disconnect between price targets from brokers and the current market price.

Despite a Buy rating with a 772-pence price target from Investec, the stock has not seen a near-term catalyst to lift it. The recent guidance cut, announced on August 7, resulted in a revised 2026 revenue forecast of £180 million-£200 million, down from the previous £220 million-£240 million range. The company cited shorter-term shifts in client ordering patterns and a phased ramp-up of its Durham, North Carolina manufacturing facility as the reasons behind the adjustment.

Investors are now scrutinizing whether Oxford BioMedica can transform its long-term growth potential into stronger near-term revenue. The company has been actively investing in its U.S. manufacturing capacity, particularly for commercial-scale cell and gene therapy work, with the Durham facility intended to bolster its U.S. commercial manufacturing capabilities.

However, the company remains vulnerable to the timing of customer programs, which can cause revenue fluctuations as projects transition from development to commercial manufacturing. Currently, the stock price oscillates between long-term analyst optimism and weaker near-term expectations, as the gap between broker targets and the current market price indicates that analysts still perceive significant value in the company.